Evidence map›Paper›PMID 40786450›Full record

ArticleJMA journal2025

Health Insurance and Its Psychosocial Correlates in Patients with Advanced Lung Cancer in Japan.

Fumimaro Ito, Takashi Sato, Kohei Horiuchi, Daisuke Arai, Keiko Ohgino, Kota Ishioka, Hideki Terai, Shinnosuke Ikemura, Hiroyuki Yasuda, Ichiro Nakachi and 10 more

Abstract read
In one paragraph

Article in JMA journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Fumimaro ItoDepartment of Medicine, Keio University School of Medicine, Tokyo, Japan.
Takashi SatoDepartment of Medicine, Keio University School of Medicine, Tokyo, Japan.
Kohei HoriuchiDepartment of Medicine, Keio University School of Medicine, Tokyo, Japan.
Daisuke AraiDepartment of Medicine, Keio University School of Medicine, Tokyo, Japan.
Keiko OhginoDepartment of Medicine, Keio University School of Medicine, Tokyo, Japan.
Kota IshiokaDepartment of Medicine, Keio University School of Medicine, Tokyo, Japan.
Hideki TeraiDepartment of Medicine, Keio University School of Medicine, Tokyo, Japan.
Shinnosuke IkemuraDepartment of Medicine, Keio University School of Medicine, Tokyo, Japan.
Hiroyuki YasudaDepartment of Medicine, Keio University School of Medicine, Tokyo, Japan.
Ichiro NakachiDepartment of Medicine, Keio University School of Medicine, Tokyo, Japan.
Ichiro KawadaDepartment of Medicine, Keio University School of Medicine, Tokyo, Japan.
Takashi InoueDepartment of Internal Medicine, Sano-Kosei General Hospital, Sano, Japan.
Yoshitaka OyamadaDepartment of Respiratory Medicine, National Hospital Organization Tokyo Medical Center, Tokyo, Japan.
Takeshi TerashimaDepartment of Respiratory Medicine, Tokyo Dental College Ichikawa General Hospital, Ichikawa, Japan.
Koichi SayamaDivision of Pulmonary Medicine, Kawasaki Municipal Kawasaki Hospital, Kawasaki, Japan.
Daisuke FujisawaDepartment of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan.
Mari TakeuchiDepartment of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan.
Koichi FukunagaDepartment of Medicine, Keio University School of Medicine, Tokyo, Japan.
Katsuhiko NaokiDepartment of Respiratory Medicine, Kitasato University School of Medicine, Sagamihara, Japan.
Kenzo SoejimaDepartment of Medicine, Keio University School of Medicine, Tokyo, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Japan has a national health insurance system that covers at least 70% of regular medical costs and provides additional benefits for high medical costs. In addition, >60% of the population holds private health insurance to reduce financial toxicity. However, there has been a lack of real-world data on private health insurance in the oncology setting in Japan. Methods: A cross-sectional survey of health insurance was conducted at 16 hospitals in Japan between 2013 and 2016. Patients were eligible if they were newly diagnosed with clinical stage IIIB or IV lung cancer. Data collected included patients' health insurance, clinical and sociodemographic characteristics, and self-reported outcomes 3 months after diagnosis. Results: Of the 147 patients, 114 (77.6%) had private health insurance. Patients with private health insurance were significantly younger (p = 0.028), had better performance status (p = 0.029), and reported better quality of life (p = 0.017), specifically in social (p = 0.039) and emotional (p = 0.011) well-being. There were no significant associations between having private health insurance and treatment details, medical satisfaction, or financial issues. Most patients (99.3%) reported that national health insurance is necessary. A substantial proportion of patients (9.8%), particularly those without private health insurance (19.4%), reported that private health insurance is not necessary. Conclusions: Having private health insurance was associated with better quality of life, though there were no significant differences in medical care or financial issues. Our findings suggest that private health insurance plays an auxiliary role in accessing medical care for patients with advanced lung cancer in Japan.

Indexed as

health insuranceJapanlung cancerprivate health insurancequality of life

Identifiers

PMID40786450
PMCPMC12329066

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.